Misako Nagasaka

机构：St. Marianna University School of Medicine, University of California, Irvine, Detroit Medical Center, University of California, Irvine Medical Center, UC Irvine Health

发表论文 429 篇 · 总被引 7735 次 · h-index 43

代表论文

• Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study (2026 · Nature Communications · 被引 6)
• Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium (2026 · Clinical Cancer Research · 被引 4)
• Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer (2026 · JCO Precision Oncology · 被引 1)
• Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma (2026 · Journal for ImmunoTherapy of Cancer · 被引 1)
• An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer (2026 · Expert Review of Anticancer Therapy · 被引 1)
• Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison (2026 · Lung Cancer)